Investors with substantial losses in Chelsea Therapeutics International Ltd. must inquire about the lead plaintiff deadline in the CHTP Class Action Securities Lawsuit by June 4, 2012 for consideration by the Court.
Chelsea Therapeutics Class Action Securities Lawsuit | (888) 252-0048
If you or someone you know suffered a net loss for all transactions in Chelsea Therapeutics International, Ltd. (CHTP) common stock during the Class Period, you are encouraged to contact our Shareholder Rights Attorneys to obtain additional information about this lawsuit and your ability to become a lead plaintiff. You may contact our experienced securities law attorneys by telephone toll free at (888) 252-0048, by e-mail at consultations@gilmanlawllp.com, or by completing the yellow form to the left of this screen for a free class action consultation. You may retain the leading national securities law firm of Gilman Law LLP to represent you in this matter without financial obligation or cost to you.
No class has yet been certified in the above action. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.
To join in or read more about the Enterprise Financial Services Corp. Class Action Securities Lawsuit.
Facebook
Twitter
RSS